Pfizer Limited

Pfizer Limited

Pfizer Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with Regulation 74(5) for the quarter ended September 30, 2026.

Pfizer Limited

Pfizer Limited has informed the Exchange about a special window for transfer and dematerialisation of physical securities, which was opened from February 5, 2026, to February 4, 2027, to facilitate investors who had their transfer requests rejected prior to April 1, 2019.

Pfizer Limited

Pfizer Limited has informed the Exchange regarding the Trading Window closure for the declaration of unaudited Financial Results for the half year ending September 30, 2026.

Pfizer Limited

Pfizer Limited has received a penalty of Rs. 1,26,34,050 from the Deputy / Additional Commissioner of Income tax Transfer Pricing for non-furnishing of specific granular information during a transfer pricing audit for the Assessment Year 2023-24.

Pfizer Limited

Pfizer Limited has informed the Exchange about Resignation of Director/KMP/SMP, indicating a change in management.

Pfizer Limited

Pfizer Limited has informed the Exchange about the resignation of a Director/KMP/SMP, but no further details are provided.

Pfizer Limited

Pfizer Limited has informed the Exchange about the resignation of Mr. Sharad Goswami, Senior Director – Policy & Public Affairs, effective September 25, 2026, to pursue opportunities outside the company.

Pfizer Limited

Pfizer Limited has announced the discontinuation of Minipress XL, a decision made by Pfizer Inc. USA, with the company to receive a lump sum payment of USD 13.9 Million (~Rs. 131.38 Crore).

Pfizer Limited

Pfizer Limited has informed the Exchange about a special window for re-lodgement of transfer and dematerialisation of physical securities, as per SEBI circulars.

Pfizer Limited

Pfizer Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on July 28, 2026. Further, the company has informed the Exchange regarding voting results. All resolutions contained in the Notice of the 75th Annual General Meeting have been duly passed by the Members with requisite majority.

Pfizer Limited

Pfizer Limited held its 75th Annual General Meeting on July 28, 2026, through video conferencing, with the requisite quorum present. The meeting was chaired by Mr. Pradip Shah, and the proceedings were recorded as per the relevant circulars. The company's performance and financial highlights for the year under review were presented, and the shareholders were informed about the corporate social responsibility programs and environmental, social, and governance initiatives. The meeting concluded with the consent of the members, and the notice convening the AGM was taken as read.

Pfizer Limited

Pfizer Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The results include a limited review report by B S R & Co. LLP, the company's statutory auditors.

Pfizer Limited

Pfizer Limited has informed the Exchange regarding Change in Director(s) of the company. Mr. Amit Agarwal, Executive Director – Finance & Chief Financial Officer, has resigned from the services of the Company, with effect from October 8, 2026, to pursue an opportunity outside Pfizer Limited.

Pfizer Limited

Pfizer Limited has temporarily discontinued Premarin Vaginal Cream in India due to supply constraints, contributing less than 1% to the company's revenue. The discontinuation is not expected to have a material impact on the company's financial performance or profitability.

Pfizer Limited

The NSE has sought clarification from Pfizer Limited regarding a news article about the company suspending Premarin vaginal cream in India, citing concerns over menopause care.

Pfizer Limited

Pfizer Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming compliance with Regulation 74(5) for the quarter ended June 30, 2026.

Pfizer Limited

Pfizer Limited has informed the Exchange regarding the 75th Annual General Meeting (AGM) and the Annual Report for the Financial Year ended March 31, 2026. The AGM will be held on July 28, 2026, through video conferencing. The Annual Report is available on the company's website and on the websites of the stock exchanges.

Pfizer Limited

Pfizer Limited has informed the Exchange about Copy of Newspaper Publication for the 75th Annual General Meeting.

Pfizer Limited

Pfizer Limited has informed the Exchange regarding Notice of the 75th Annual General Meeting to be held on July 28, 2026, through Video Conferencing (‘VC’) / Other Audio-Visual Means (‘OAVM’) to transact the following business: To consider and pass the following resolution as an Ordinary Resolution: Item No. 1 – Adoption of the Audited Financial Statements. Item No. 2 – Declaration of Dividend. Item No. 3 – To appoint a Director in place of Mr. P. Rengan (DIN: 10362899) as a Director, liable to retire by rotation. The Board of Directors at its meeting held on May 12, 2026, has recommended a final dividend of Rs. 75/- per equity share of Rs. 10/- each (750%) for the financial year ended March 31, 2026.

Pfizer Limited

Pfizer Limited has closed its trading window for trading in its shares from June 30, 2026, until 48 hours after the unaudited financial results for the quarter ending June 30, 2026, are made public.